Login/Register

News

TaiMed Biologics Advances Long-Acting HIV Trials and Enters US$400 Billion Autoimmune Market

At the J.P. Morgan Healthcare Conference Taipei on March 10, CEO James Chang announced TaiMed's evolution into a dual-platform model: "Long-acting HIV Therapy + Precision Autoimmune Treatment."

Read more
Feb 11, 2026
Feb 10, 2026
Feb 10, 2026
Feb 10, 2026
Feb 10, 2026
Feb 09, 2026
Feb 09, 2026
Feb 09, 2026
Feb 09, 2026